Regulus Therapeutics Inc (NASDAQ:RGLS)’s traded shares stood at 0.83 million during the last session, with the company’s beta value hitting 1.02. At the close of trading, the stock’s price was $1.78, to imply an increase of 3.49% or $0.06 in intraday trading. The RGLS share’s 52-week high remains $2.90, putting it -62.92% down since that peak but still an impressive 53.37% since price per share fell to its 52-week low of $0.83. The company has a valuation of $117.91M, with an average of 1.12 million shares in intraday trading volume over the past 10 days and average of 1.16 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Regulus Therapeutics Inc (RGLS), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give RGLS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.26.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
After registering a 3.49% upside in the last session, Regulus Therapeutics Inc (RGLS) has traded red over the past five days. The 5-day price performance for the stock is 5.64%, and 28.99% over 30 days. With these gigs, the year-to-date price performance is 12.66%. Short interest in Regulus Therapeutics Inc (NASDAQ:RGLS) saw shorts transact 2.04 million shares and set a 6.49 days time to cover.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 40.21% for the past 5-year period. While 2025 is set for a -42.89% return in earnings, projections for the next 5 years are at -3.70% annually.
RGLS Dividends
Regulus Therapeutics Inc has its next earnings report out on 2025-Mar-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
Regulus Therapeutics Inc insiders hold 2.18% of total outstanding shares, with institutional holders owning 82.47% of the shares at 84.31% float percentage. In total, 82.47% institutions holds shares in the company, led by FEDERATED HERMES, INC.. As of 2024-06-30, the company held over 12.85 million shares (or 19.9374% of shares), all amounting to roughly $22.94 million.
The next major institution holding the largest number of shares is RA CAPITAL MANAGEMENT, L.P. with 6.25 million shares, or about 9.6952% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $11.16 million.
We also have Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund as the top two Mutual Funds with the largest holdings of the Regulus Therapeutics Inc (RGLS) shares. Going by data provided on Jan 31, 2025 , Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund holds roughly 7.88 shares. This is just over 11.90% of the total shares, with a market valuation of $14.03 million. Data from the same date shows that the other fund manager holds a little less at 7.42, or 11.20% of the shares, all valued at about 13.2 million.
